Use: Labeled indications
- Acyclovir tablets are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes.
- Acyclovir tablets are indicated for the treatment of chickenpox (varicella).
Full indications and usage US FDA label
INDICATIONS AND USAGE Herpes Zoster Infections: Acyclovir tablets are indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir tablets are indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Acyclovir tablets are indicated for the treatment of chickenpox (varicella).
Contraindications
- Clinically significant hypersensitivity (e.g., anaphylaxis, severe cutaneous adverse reactions) to acyclovir, valacyclovir or any component of the formulation
Contraindications (US label) US FDA label
CONTRAINDICATIONS Acyclovir is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction [e.g., anaphylaxis, severe cutaneous adverse reactions (SCARs)] to acyclovir, valacyclovir, or any component of the formulation (see WARNINGS and ADVERSE REACTIONS).
Dosing: Adult
- Herpes zoster (acute): 800 mg orally every 4 hours, 5 times daily, for 7 to 10 days
- Genital herpes, initial episode: 200 mg every 4 hours, 5 times daily, for 10 days
- Genital herpes, chronic suppression: 400 mg twice daily for up to 12 months, then re-evaluate
- Chickenpox (adults and children over 40 kg): 800 mg 4 times daily for 5 days
- Herpes simplex encephalitis (IV): 10 mg/kg every 8 hours for 10 days, infused over 1 hour
- Mucocutaneous HSV in immunocompromised patients (IV): 5 mg/kg every 8 hours for 7 days
- Severe initial genital herpes (IV): 5 mg/kg every 8 hours for 5 days
- Varicella-zoster in immunocompromised patients (IV): 10 mg/kg every 8 hours for 7 days
- IV dosing rules: Obese patients: dose by ideal body weight; never exceed 20 mg/kg every 8 hours; no bolus, intramuscular or subcutaneous injection
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Acute Treatment of Herpes Zoster: 800 mg every 4 hours orally, 5 times daily for 7 to 10 days. Genital Herpes: Treatment of Initial Genital Herpes: 200 mg every 4 hours, 5 times daily for 10 days. Chronic Suppressive Therapy for Recurrent Disease: 400 mg 2 times daily for up to 12 months, followed by re-evaluation.
Alternative regimens have included doses ranging from 200 mg 3 times daily to 200 mg 5 times daily. The frequency and severity of episodes of untreated genital herpes may change over time. After 1 year of therapy, the frequency and severity of the patient's genital herpes infection should be re-evaluated to assess the need for continuation of therapy with acyclovir.
Intermittent Therapy: 200 mg every 4 hours, 5 times daily for 5 days. Therapy should be initiated at the earliest sign or symptom (prodrome) of recurrence. Treatment of Chickenpox: Children (2 years of age and older): 20 mg/kg per dose orally 4 times daily (80 mg/kg/day) for 5 days. Children over 40 kg should receive the adult dose for chickenpox.
Adults and Children over 40 kg: 800 mg 4 times daily for 5 days. Intravenous acyclovir is indicated for the treatment of varicella-zoster infections in immunocompromised patients. When therapy is indicated, it should be initiated at the earliest sign or symptom of chickenpox. There is no information about the efficacy of therapy initiated more than 24 hours after onset of signs and symptoms.
Patients With Acute or Chronic Renal Impairment: In patients with renal impairment, the dose of acyclovir tablets should be modified as shown in Table 3. Table 3. Dosage Modification for Renal Impairment Normal Dosage Regimen Creatinine Clearance (mL/min/1.73 m²) Adjusted Dosage Regimen Dose (mg) Dosing Interval 200 mg every 4 hours >10 0 to 10 200 200 every 4 hours, 5x daily every 12 hours 400 mg every 12 hours >10 0 to 10 400 200 every 12 hours every 12 hours 800 mg every 4 hours >25 10 to 25 0 to 10 800 800 800 every 4 hours, 5x daily every 8 hours every 12 hours Hemodialysis: For patients who require hemodialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours.
This results in a 60% decrease in plasma concentrations following a 6-hour dialysis period. Therefore, the patient's dosing schedule should be adjusted so that an additional dose is administered after each dialysis. Peritoneal Dialysis: No supplemental dose appears to be necessary after adjustment of the dosing interval.
Bioequivalence of Dosage Forms: Acyclovir suspension was shown to be bioequivalent to acyclovir capsules (n = 20) and 1 acyclovir 800-mg tablet was shown to be bioequivalent to 4 acyclovir 200-mg capsules (n = 24).
Dosing: Altered kidney function
Acyclovir is cleared by the kidneys, so the US labels lengthen the dosing interval (oral) or lower the dose and interval (intravenous, IV) by creatinine clearance (CrCl), and add a dose after each hemodialysis session. Oral and IV tables differ; do not transpose doses. IV: infuse over at least 1 hour (renal tubular damage), keep the patient well hydrated (acyclovir can precipitate in the renal tubules), and dose obese patients by ideal body weight (label).
Kidney function measure: Label uses creatinine clearance indexed to body surface area (mL/min/1.73 m2).
Show full dosing details
- CrCl ≥60 mL/min/1.73 m2
- Oral: usual dosing. IV: usual dose every 8 hours (label: CrCl >50).
- CrCl 30–59 mL/min/1.73 m2
- Oral: no change for 200 mg or 400 mg regimens (CrCl >10) or 800 mg five times daily (CrCl >25) (label). IV: CrCl >50, every 8 hours; CrCl 25–50, 100% of the dose every 12 hours (label).
- CrCl 15–29 mL/min/1.73 m2
- Oral: 800 mg every 4 hours regimen: CrCl 10–25, 800 mg every 8 hours; 200 mg and 400 mg regimens unchanged (CrCl >10) (label). IV: CrCl 25–29, every 12 hours; CrCl 10–25, 100% of the dose every 24 hours (label).
- CrCl <15 mL/min/1.73 m2 (not on dialysis)
- Oral: CrCl 10–25, 800 mg every 8 hours; CrCl 0–10, 200 mg every 12 hours (200 mg and 400 mg regimens) or 800 mg every 12 hours (800 mg regimen). IV: CrCl 10–25, 100% of the dose every 24 hours; CrCl 0–10, 50% of the dose every 24 hours (label). Neurotoxicity can occur even at adjusted doses.
- Hemodialysis (intermittent)
- Oral: use the CrCl 0–10 regimen (200 mg every 12 hours for the 200 mg and 400 mg regimens; 800 mg every 12 hours for the 800 mg regimen). IV: 50% of the dose every 24 hours (CrCl 0–10). Schedule a dose right after each dialysis; a 6-hour session lowers levels by about 60% (label). Watch for neurotoxicity (confusion, hallucinations, seizures), which can occur even at adjusted doses.
- Peritoneal dialysis
- No supplemental dose needed after adjusting the interval (oral and IV labels).
- CRRT
- Not in the labels. Published CRRT regimen (IV): 5 to 7.5 mg/kg every 24 hours; therapeutic drug monitoring where available (Li 2020).
- Dialyzable? Yes: half-life about 5 hours during hemodialysis (label).
- Monitoring Kidney function and hydration. Neurotoxicity (confusion, hallucinations, dysarthria, seizures) is most common in end-stage kidney disease (ESKD) and older adults, including at adjusted doses; stop the drug and consider hemodialysis if it occurs.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Normal kidney function: usual pediatric dosing (label).
- eGFR 30–59
- IV label table (CrCl in mL/min/1.73 m2, not restricted by age): 25–50, 100% every 12 hours; 10–25, 100% every 24 hours; 0–10, 50% every 24 hours. Neither label states pediatric validation; specialist input.
- eGFR 15–29
- IV label table (CrCl in mL/min/1.73 m2, not restricted by age): 25–50, 100% every 12 hours; 10–25, 100% every 24 hours; 0–10, 50% every 24 hours. Neither label states pediatric validation; specialist input.
- eGFR <15 (not on dialysis)
- IV label table (CrCl in mL/min/1.73 m2, not restricted by age): 25–50, 100% every 12 hours; 10–25, 100% every 24 hours; 0–10, 50% every 24 hours. Neither label states pediatric validation; specialist input.
- Hemodialysis (intermittent)
- No pediatric data in label. Specialist input.
- Peritoneal dialysis
- No pediatric data.
- CRRT
- No pediatric data.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Renal Impairment: In patients with renal impairment, the dose of acyclovir tablets should be modified as shown in Table 3. Table 3. Dosage Modification for Renal Impairment Normal Dosage Regimen Creatinine Clearance (mL/min/1.73 m²) Adjusted Dosage Regimen Dose (mg) Dosing Interval 200 mg every 4 hours >10 0 to 10 200 200 every 4 hours, 5x daily every 12 hours 400 mg every 12 hours >10 0 to 10 400 200 every 12 hours every 12 hours 800 mg every 4 hours >25 10 to 25 0 to 10 800 800 800 every 4 hours, 5x daily every 8 hours every 12 hours Hemodialysis: For patients who require hemodialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours.
This results in a 60% decrease in plasma concentrations following a 6-hour dialysis period. Therefore, the patient's dosing schedule should be adjusted so that an additional dose is administered after each dialysis. Peritoneal Dialysis: No supplemental dose appears to be necessary after adjustment of the dosing interval.
Bioequivalence of Dosage Forms: Acyclovir suspension was shown to be bioequivalent to acyclovir capsules (n = 20) and 1 acyclovir 800-mg tablet was shown to be bioequivalent to 4 acyclovir 200-mg capsules (n = 24).
Impaired Renal Function: The half-life and total body clearance of acyclovir are dependent on renal function. A dosage adjustment is recommended for patients with reduced renal function (see DOSAGE AND ADMINISTRATION).
Dosing: Pediatric
- Approved ages
- Oral: not established under 2 years (oral label). IV: from birth (neonatal HSV) and for children under 12 years with HSV or varicella-zoster infections (IV label).
- Usual dose
- Oral chickenpox, 2 years and older: 20 mg/kg 4 times daily for 5 days. IV, under 12 years: mucocutaneous HSV in immunocompromised 10 mg/kg every 8 hours for 7 days; HSV encephalitis (3 months to 12 years) 20 mg/kg every 8 hours for 10 days; varicella-zoster in immunocompromised 20 mg/kg every 8 hours for 7 days (labels).
- Maximum dose
- Oral: over 40 kg, adult dose. IV: never more than 20 mg/kg every 8 hours for any patient (IV label).
- Neonates
- Neonatal HSV, birth to 3 months (IV): 10 mg/kg every 8 hours for 10 days; 15 or 20 mg/kg every 8 hours has been used, but its safety and efficacy are not known (IV label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Tablet: 200 mg, 400 mg, 800 mg
- Cream: 5 g per 100 g, 50 mg/g
- Capsule: 200 mg, 400 mg
- Topical cream: 50 mg/g
- Lyophilized powder for injection: 250 mg
- Suspension: 200 mg per 5 mL, 200 mg/5 mL, 400 mg/5 mL
- Ophthalmic ointment: 30 mg/g
- Film-coated tablet: 200 mg, 800 mg
- Powder for injection: 250 mg
- Solution for iv infusion: 25 mg/mL
and 6 more forms; see the products table.
Registered products in the Philippines
102 products registered with the Food and Drug Administration (FDA) Philippines list Acyclovir as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: AcicIovir (1 product) · Aciclovar (1 product) · Aciclovir (88 products). Products registered under these spellings are included in the table and marked.
All registered products102
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
200 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-6344-01 | Apr 5, 2028 | ||
400 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | EBA Generisch Trading Inc. | DRP-6343-01 | Apr 5, 2028 | ||
400mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | S Kant Healthcare Ltd.India | Medinova Pharmaceutical, Inc. | DRP-12579 | Sep 8, 2027 | ||
50 mg/g (5% w/w) CreamAluminum Tube x 5 g (Box of 1’s) | Rx | Agio Pharmaceuticals Ltd.India | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-2475-02 | Mar 16, 2037 | ||
50 mg/g CreamLaminated Plastic Tube x 10 g (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | Speed Med Pharmaceuticals Inc. | DRP-8719-03 | Aug 19, 2031 | ||
400 mg TabletAlu-PVC Blister Pack x 10's (Box of 100's) | Rx | Sai Parenterals Ltd.TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India | Eliset Pharmaceutical, Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12771-01 | Apr 25, 2030 | ||
200 mg TabletClear PVC Blister Pack x 10's (Box of 20's) | Rx | Agio Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-3203 | Apr 23, 2027 | ||
50 mg/g (5% w/w) CreamAluminum Tube x 5 g (Box of 1’s) | Rx | Agio Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-2475 | Feb 15, 2037 | ||
400 mg TabletPVC/PVDC-Alu Blister Pack x 8's (Box of 80's) | Rx | Hetero Labs LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-7719 | Mar 6, 2028 | ||
800 mg TabletPVC/PVDC-Alu Blister Pack x 10's Box of 100's | Rx | Hetero Labs LimitedIndia | Camber Pharmaceuticals, Inc. | DRP-7720 | Mar 6, 2028 | ||
50 mg/g (5% w/w) CreamAluminum Collapsible Tube X 5g with White Cap (Box of 1’s) | Rx | Yash Medicare Private LimitedIndia | The Cathay Drug Co., Inc.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-13439 | Sep 20, 2027 | ||
50 mg/g CreamLaminated Plastic Tube in 10 g (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | The Cathay Drug Co., Inc. | DRP-8719-01 | Jul 30, 2031 | ||
50 mg/g (5% w/w) Topical Cream5 g Aluminum tube | Rx | S Kant Healthcare LimitedIndia | Aglobal Care, Inc. | DRP-16276 | Jan 22, 2030 | ||
30 mg/g (3% w/w ) Ophthalmic OintmentIn Aluminum collapsible tube x 5 g (Box of 1's) | Rx | Aristopharma Ltd.Bangladesh | Sahar International Trading, Inc. | DRP-7034 | Jan 22, 2030 | ||
AsimplexAcyclovir | 250mg Lyophilized Powder for Solution for IV InfusionType I Colorless Glass Vial with Bromobutyl Rubber Stopper covered by Flip-off Cap (Box of l's) | Rx | Aroma İlaç San. Ltd. ŞTİTurkey | Medinova Pharmaceutical Inc.Trader: Polifarma Ilaç San. Ve Tic. A.Ş. | DRP-11371 | Mar 7, 2027 | |
400 mg tabletAlu/PVC Blister pack x 10's (Box of 30's) | Rx | Scheele Laboratories Phils., Inc.Philippines | Avantmed International Pharma, Inc. | DRP-4456-01 | Jun 6, 2028 | ||
800 mg TabletPVC/Alu Blister Pack x 10's (Box of 20's) | Rx | Scheele Laboratories Phils., Inc.Philippines | Avantmed International Pharma, Inc. | DRP-5471-01 | Jan 22, 2028 | ||
200 mg/5 mL Oral SuspensionAmber Bottle x 60 mL (Box of 1's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DR-XY23683 | Oct 1, 2031 | ||
400mg TabletBlister Foil x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Laguna | — | DRP-4057 | Sep 8, 2031 | ||
800 mg TabletAlu/PVC blister pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-11609 | Apr 4, 2027 | ||
BeclovirAcyclovir | 800 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Uni MedicolabsIndia | Best Remedy Medicines Pharmaceutical Co.Importer: Greencore Pharma Inc. | DRP-17897-01 | Mar 31, 2031 | |
250 mg Lyophilized Powder For Injection (IV Infusion)Ph. Eur. Type II clear and colorless vial sealed with chlorobutyl rubber stopper and an aluminum cap with green flip-off seal (Box of 1's) | Rx | Laboratorio Reig Jofre S.A.Spain | Penta Labs Australia (Philippines) | DRP-12582 | Sep 14, 2027 | ||
Blicyclo 400Acyclovir | 400 mg TabletAlu/Clear PVC blister pack x 10's (Box of 100's) | Rx | Next Wave (India)India | Bliss Pharma Distribution and Consultancy Corp. | DRP-16797 | Jul 11, 2030 | |
50 mg/g (5% w/w) CreamAluminum Tube with Cap x 10 g (Box of 1's) | Rx | Front Pharmaceutical PLCChina | AMB HK Enterprises Inc. | DRP-17080 | Sep 23, 2030 | ||
ClovicoreAcyclovir | 800 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Uni MedicolabsIndia | Greencore Pharma Inc. | DRP-17897 | Mar 31, 2031 | |
200 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | XL Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-2290 | Jun 29, 2031 | ||
800 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | XL LABORATORIES PVT. LTD.India | Labmate Pharma Inc.Importer: Ambica International Corporation | DRP-1669 | Oct 21, 2031 | ||
400 mg TabletAlu/Alu Blister Pack x 10's Box of 30's | Rx | XL Laboratories Pvt. Ltd.India | Labmate Pharma Inc.Importer: Ambica International Corporation | DRP-2959 | Jan 5, 2030 | ||
ClovirasiAcyclovir (as sodium) | 250 mg Powder for InjectionUSP Type III Flint Glass Vial with Grey Bromobutyl Rubber Stopper and Flip-off Seal x 10 mL (Box 1's) | Rx | Indasi Lifescience Pvt. Ltd.India | Aglobal Care, Inc. | DRP-15539 | Jul 31, 2029 | |
800 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 20's) | Rx | Brookes Pharma Private LmitedPakistan | Sahar International Trading Inc. | DR-XY40039 | Sep 15, 2036 | ||
50 mg/g (5% w/w) Topical CreamAluminum Collapsible Tube x 5 g (Box of 1's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DRP-8033 | Nov 27, 2031 | ||
800 mg TabletAluminum Foil Strip x 5's Box of 25's | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DR-XY30158 | Dec 19, 2029 | ||
50 mg/g (5% w/w) CreamAluminum tube x 5g (Box of l’s) | Rx | Dae Hwa Pharmaceutical Co., Ltd.Korea | H & B Pharma International Inc. | DRP-12092 | Jun 10, 2027 | ||
200 mg TabletBlister Pack x 5's Box of 25's | Rx | STADA Arzneimittel AGGermany | STADA Philippines Inc. | DRP-2916 | Apr 22, 2027 | ||
50 mg/g CreamAluminum Tube x 2 g and 5 g | Rx | STADA Arzneimittel AGGermany | STADA Philippines Inc. | DRP-2914 | Dec 23, 2029 | ||
800 mg TabletAlu/White Opaque PVC/PVDC Blister Pack x 5's (Box of 10's and 35’s) | Rx | STADA Arzneimittel AGGermany | STADA Philippines Inc. | DRP-9037 | Aug 7, 2030 | ||
800 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | XL Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-1669-02 | Feb 7, 2032 | ||
400 mg TabletAlu/Alu Blister Pack x 10's Box of 30’s | Rx | XL Laboratories Pvt. Ltd.India | AJ Research & Pharma Inc.Importer: Ambica International Corporation | DRP-2959-01 | Jan 5, 2030 | ||
50 mg / g (5% w/w) CreamAluminum Collapsible Tube x 5g with White Cap (Box of 1’s) | Rx | Yash Medicare Private LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-13439-01 | Sep 20, 2027 | ||
400 mg/5 mL SuspensionAmber Glass Bottle (Type III) with LDPE Flip-off Cap x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Folares Pharmaceuticals, Inc. | DR-XY35361 | Nov 3, 2031 | ||
5% OintmentAluminum Tube x 5 grams (Box of 1's) | Rx | Micro Labs LimitedIndia | Brown & Burk Philippines, Inc. | DR-XY30349 | Nov 23, 2029 | ||
200 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Korea United Pharm. Inc.Republic of Korea | Metropolitan Pharmaceutical Products, Inc. | DR-XY25789 | Mar 7, 2028 | ||
400 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Korea United Pharm., Inc.Republic of Korea | Metropolitan Pharmaceutical Products, Inc. | DR-XY25788 | Feb 4, 2030 | ||
800 mg Tablet | Rx | Korea United Pharm. Inc. | Metropolitan Pharmaceutical Products, Inc. | DR-XY30731 | May 3, 2027 | ||
50 mg/g (5% w/w) Topical CreamAluminum collapsible tube x 10g (Box of 1's) | Rx | Front Pharmaceutical PLCChina | Hexagon Pharmaceuticals | DRP-15088 | Apr 18, 2029 | ||
200 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's & 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | KONZEPT CONVENIENCE AND DRUG STORE CORP. | DRP-6344-02 | Apr 5, 2028 | ||
400 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's & 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | KONZEPT CONVENIENCE AND DRUG STORE CORP. | DRP-6343-02 | Apr 5, 2028 | ||
KlozivexAcyclovir | 50 mg/g (5 % w/w) CreamAluminum PP Collapsible Tube x 5 g (Box of 1's) | Rx | Torrent Pharmaceuticals LimitedIndia | Torrent Pharma Philippines, Inc. | DR-XY47707 | Feb 17, 2032 | |
50 mg/g (5% w/w) Topical OintmentAluminum collapsible tube with white HDPE cap x 15 g and 30 g (Box of 1's) | Rx | ENCUBE ETHICALS PVT. LTD.India | Torrent Pharma Philippines, Inc.Trader: Torrent Pharmaceuticals Ltd. | DR-XY48969 | Jan 2, 2029 | ||
LovirAcyclovir (as sodium) | 250 mg Powder for Injection (IV)Type I Clear and Colorless Glass Vial with Blue Flip-Off Seal x 1's (Box of 10's) | Rx | Ciron Drugs & Pharmaceuticals Pvt., Ltd.India | Importer: Phil Pharmawealth Inc.Trader: Oboi Laboratories | DR-XY37027 | Nov 18, 2029 | |
200 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | Rx | Pascual Laboratories, Inc.Philippines | Pharex Health Corporation | DR-XY30694 | May 9, 2031 | ||
200 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Medico Remedies LimitedIndia | Medico Remedies Limited | DRP-14657 | Nov 17, 2028 | ||
30 mg/g (3% w/w) Ophthalmic OintmentCollapsible Aluminum tube x 3.5 g w/ HDPE Plastic Cap (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Vista Pharma, Inc. | DR-XY39201 | Jun 26, 2027 | ||
5 g per 100 g Cream5 g Aluminum Tube | Rx | Kotra Pharma (M) Sdn. Bhd.Malaysia | Bliss Pharma Distribution and Consultancy Corp. | DR-XY46345 | May 18, 2028 | ||
50 mg /g (5% w/w) CreamCollapsible aluminum tube with plastic screw cap x 2 g and 5 g Box of 1's | Rx | Amherst Laboratories, Inc.Philippines | — | DR-XY46274 | Mar 7, 2028 | ||
800 mg TabletFoil Strip x 6's (Box of 30's) | Rx | Unilab, Inc.Philippines | Ritemed Phils., Inc. | DR-XY35460 | Feb 16, 2029 | ||
50 mg/g (5% w/w) Topical Cream5 g Collapsible aluminum tube (Box of 1's) | Rx | S Kant Healthcare Ltd.India | Medinova Pharmaceutical, Inc. | DRP-12684 | Sep 23, 2027 | ||
50 mg/g CreamLaminated Plastic Tube x 10 g (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-8719 | Sep 14, 2031 | ||
30 mg/g (3% w/w) Ophthalmic OintmentAluminum Collapsible Tube x 4.5 g (Box of 1’s) | Rx | Remington Pharmaceutical Industries (Pvt.) Ltd.Pakistan | Ophthamed Pharma Corp. | DR-XY43358 | Apr 16, 2029 | ||
50 mg/g (5% w/w) CreamCollapsible Aluminum Tube x 5 g (Box of l's) | Rx | Kolmar Korea Co., Ltd.Korea | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-11603 | Mar 31, 2027 | ||
SaphrivaxAcyclovir | 50 mg/g (5% w/w) Cream5 g, 10 g, 15 g, 20 g and 30 g Aluminum Collapsible Tube (Box of 1's) | Rx | Azine Healthcare Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd | DRP-13432 | Feb 17, 2028 | |
200 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Sai Parenterals Ltd.India | Nelpa Lifesciences Inc., | DRP-13572 | Sep 15, 2030 | ||
400 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences Inc. | DRP-17753 | Mar 12, 2031 | ||
200 mg per 5 mL Suspension (Banana Flavor)60 mL Boston Round Amber Bottle fitted with 20 mm Foam-lined PP Aluminum Cap, containing 50 mL Suspension (Box of 1's) | Rx | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-6170 | Jun 15, 2031 | ||
400 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-1635 | Sep 18, 2029 | ||
800 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-1605 | Jun 19, 2029 | ||
25 mg/mL Solution for IV infusion | Rx | Baxter Pharmaceuticals India Private Limited | — | DRP-7639 | Dec 14, 2026 | ||
200 mg TabletBlister Pack of 10's Box of 100's | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY31055 | Sep 6, 2027 | ||
400 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY31054 | Sep 6, 2027 | ||
200 mg CapsuleAluminum Foil Strip Pack x 10's (Box of 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-6094 | Mar 27, 2031 | ||
200 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DR-XY24393 | Oct 8, 2031 | ||
25 mg/mL Solution for IV Infusion | Rx | Baxter Pharmaceuticals India Private Limited | — | DRP-7639-01 | Dec 14, 2026 | ||
50 mg/g CreamLaminated Plastic Tube x 10 g (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | Icon Healthcare, Inc. | DRP-8719-02 | Aug 13, 2031 | ||
50 mg/g (5% w/w) Topical CreamLaminated Tube x 10 g (Box of 1's) | Rx | Helios Pharmaceuticals (Division of P.K.T.P. PrivateIndia | Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-16277 | Jan 22, 2030 | ||
200 mg TabletBlister Pack x 10's (Box of 10's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Eadriex Pharmaceuticals Phils., Inc. | DR-XY27411 | Apr 1, 2027 | ||
400 mg TabletAlu/Clear PVC Blister Pack x 5's (Box of 25's) | Rx | Hovid BerhadMalaysia | Hovid Inc. | DR-XY28738 | Jul 4, 2028 | ||
50 mg/g (5% w/w) CreamAluminum tube x 5 g (Box of 1's) | Rx | Hovid Bhd.Malaysia | Hovid Inc. | DR-XY30629 | Mar 31, 2030 | ||
50 mg/g (5% w/w) OintmentLaminated collapsible tube x 15 g (Box of 1's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-14608 | Oct 27, 2028 | ||
250 mg Lyophilized Powder for Injection (I.V. Infusion)10 mL-capacity USP Type I clear and colorless glass vial with grey butyl rubber stopper and aluminum seal with red plastic flip-off cap (Box of l’s) | Rx | United Biotech Pvt. Ltd.India | Triple Tact Import & Export Corp. | DRP-12040 | Jun 1, 2027 | ||
200 mg TabletAlu / Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | — | DRP-3960 | Feb 1, 2031 | ||
400 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's) | Rx | Scheele Laboratories Phils., Inc.Philippines | — | DRP-4456 | Jun 6, 2028 | ||
800 mg TabletPVC/Alu Blister pack x 10's (Box of 20's) | Rx | Scheele Laboratories Phils., Inc.Philippines | — | DRP-5471 | Jan 22, 2028 | ||
YoviroAcyclovir | 250 mg Lyophilized Powder for Injection (I.V)USP Type 1 Amber Glass Vial with Butyl Chloride Rubber Stopper and Aluminium Plastic Cap x 10 mL (Box of 1's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Furen Pharmaceutical Group Co., Ltd. | DRP-15370 | Jun 27, 2029 | |
200 mg TabletBlister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-444 | Jun 18, 2027 | ||
400 mg TabletAlu/PVC Blister Pack x 10’s (Box of 30’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DR-XY36314 | Jul 23, 2029 | ||
ZoviraxAcyclovir | 200mg TabletAlu-PVC Blister Pack x 5's (Box of 25's) | Rx | Glaxo Wellcome S.A.Spain | Importer: GlaxoSmithKline Philippines, Inc. | DR-XY2013 | Mar 18, 2031 | |
ZoviraxAcyclovir | 250 mg Powder for Intravenous (IV) InfusionClear and Colorless Glass Vial with Blue Flip -Off Seal (Box of 5’s) | Rx | GlaxoSmithKline Manufacturing S.P.A.Italy | GlaxoSmithKline Philippines, Inc. | DR-XY1599 | Sep 24, 2031 | |
400 mg TabletAlu/PVC Blister Pack x 5's (Box of 25's) | Rx | Glaxo Wellcome S.A.Spain | Importer: GlaxoSmithKline Philippines, Inc. | DR-XY8177 | Mar 18, 2031 | ||
50 mg/g (5% w/w) CreamCollapsible Aluminum Tube x 2 g (Box of 1's) | Rx | Glaxo Operations UK LimitedUK | GlaxoSmithKline Philippines, Inc. | DR-XY3546 | Nov 4, 2029 | ||
ZoviraxAcyclovir | 800 mg TabletAlu-PVC Blister Pack x 5's (Box of 35's) | Rx | Glaxo Wellcome S.A.Spain | GlaxoSmithKline Philippines, Inc. | DR-XY16137 | Mar 18, 2031 | |
25mg/mL (250mg/10mL) Solution for IV Infusion10 mL Type I clear and colorless glass vial closed with gray chlorobutyl rubber stopper and aluminum green flip-off cap (Box of 10's) | Rx | Korea United Pharm. Inc.Korea | United Douglas Pharm Philippines Inc. | DR-XY48764 | Jun 6, 2028 | ||
250 mg Lyophilized Powder for Injection (IV Infusion)USP Type I Clear and Colorless glass vial Box of 10's | Rx | Furen Pharmaceutical Group Co. LtdChina | Endure Medical, Inc. | DR-XY46513 | Feb 1, 2029 | ||
200 mg/ 5 mL Suspension60 mL Amber Glass Bottle in a Box | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Starpharm, Inc. | DRP-4182-03 | Aug 11, 2029 | ||
200 mg CapsuleAlu/Clear PVC Blister Pack x 10's Box of 30's and 100's | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-6344 | Apr 5, 2028 | ||
200 mg/ 5 mL Suspension60 mL Amber Glass Bottle in a box | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-4182 | Aug 11, 2029 | ||
400 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-6343 | Apr 5, 2028 | ||
200 mg TabletAlu/Clear PVC Blister Pack x 10's Box of 30's | Rx | U Square Lifescience Pvt. Ltd.India | ENDURE MEDICAL, INC.Importer: SKINGEN BIOTECH, INC. | DR-XY40780 | Mar 26, 2027 | ||
800 mg TabletAlu/Clear PVC blister pack x 10's Box of 30's | Rx | U Square Lifescience Pvt. Ltd.India | Endure Medical, Inc.Importer: Skingen Biotech, Inc. | DR-XY41060 | Jul 20, 2027 | ||
200 mg TabletClear PVC Blister Pack x 10's (Box of 20's) | Rx | Agio Pharmaceuticals LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3203-01 | Apr 23, 2027 | ||
800 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | Rx | Xl Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-1669-01 | Dec 13, 2031 | ||
50 mg/g (5% w/w) CreamAluminum Tube x 5 g (Box of 1’s) | Rx | Agio Pharmaceuticals Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-2475-01 | Mar 18, 2037 | ||
50 mg/g (5% w/w) Topical OintmentAluminum collapsible tube with white HDPE cap x 15 g and 30 g (Box of 1's) | Rx | Encube Ethicals Pvt. Ltd.India | Torrent Pharma Philippines, Inc.Trader: Torrent Pharmaceuticals Ltd. | DRP-16278 | Jan 22, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS Acyclovir tablets are intended for oral ingestion only. Renal failure, in some cases resulting in death, has been observed with acyclovir therapy (see ADVERSE REACTIONS: Observed During Clinical Practice and OVERDOSAGE). Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy.
Severe cutaneous adverse reactions (SCARs), including acute generalized exanthematous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens- Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme (EM) have been reported with acyclovir (see CONTRAINDICATIONS and ADVERSE REACTIONS). Discontinue acyclovir immediately if a painful rash with mucosal involvement or a progressive severe rash develops.
Closely monitor clinical status and initiate appropriate therapy. Acyclovir is contraindicated in patients who have developed SCARs with the use of acyclovir or valacyclovir, or any component of the formulation (see CONTRAINDICATIONS and ADVERSE REACTIONS).
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Probenecid | Adjust or monitor | Raised acyclovir half-life and AUC and lowered urinary excretion and renal clearance (studied with IV acyclovir). | The label states the effect without a dose rule; account for it when kidney function is reduced. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Malaise (11.5%, herpes zoster trials)
- Nausea (4.8%) and diarrhea (2.4%) with 1-year suppression
- Nausea and/or vomiting (2.7%, short-course genital herpes)
- Diarrhea (3.2%, chickenpox trials)
- IV: injection-site inflammation or phlebitis (about 9%), transient rise in serum creatinine or BUN (5% to 10%, more with rapid infusion), nausea or vomiting (about 7%)
Serious
- Renal failure, in some cases fatal
- Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) in immunocompromised patients
- Neurologic reactions (confusion, hallucinations, seizure, encephalopathy; postmarketing)
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Herpes Simplex: Short-Term Administration: The most frequent adverse events reported during clinical trials of treatment of genital herpes with acyclovir 200 mg administered orally 5 timesdaily every 4 hours for 10 days were nausea and/or vomiting in 8 of 298 patient treatments (2.7%). Nausea and/or vomiting occurred in 2 of 287 (0.7%) patients who received placebo.
Long-Term Administration: The most frequent adverse events reported in a clinical trial for the prevention of recurrences with continuous administration of 400 mg (two 200-mg capsules) 2 times daily for 1 year in 586 patients treated with acyclovir were nausea (4.8%) and diarrhea (2.4%). The 589 control patients receiving intermittent treatment of recurrences with acyclovir for 1 year reported diarrhea (2.7%), nausea (2.4%), and headache (2.2%).
Herpes Zoster: The most frequent adverse event reported during 3 clinical trials of treatment of herpes zoster (shingles) with 800 mg of oral acyclovir 5 times daily for 7 to 10 days in 323 patients was malaise (11.5%). The 323 placebo recipients reported malaise (11.1%). Chickenpox: The most frequent adverse event reported during 3 clinical trials of treatment of chickenpox with oral acyclovir at doses of 10 to 20 mg/kg 4 times daily for 5 to 7 days or 800 mg 4 times daily for 5 days in 495 patients was diarrhea (3.2%).
The 498 patients receiving placebo reported diarrhea (2.2%). Observed During Clinical Practice: In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of acyclovir. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.
These events have been chosen for inclusion due to either their seriousness, frequency of reporting, potential causal connection to acyclovir, or a combination of these factors. General: Anaphylaxis, angioedema, fever, headache, pain, peripheral edema. Nervous: Aggressive behavior, agitation, ataxia, coma, confusion, decreased consciousness, delirium, dizziness, dysarthria, encephalopathy, hallucinations, paresthesia, psychosis, seizure, somnolence, tremors.
These symptoms may be marked, particularly in older adults or in patients with renal impairment (see PRECAUTIONS). Digestive: Diarrhea, gastrointestinal distress, nausea. Hematologic and Lymphatic: Anemia, leukocytoclastic vasculitis, leukopenia, lymphadenopathy, thrombocytopenia. Hepatobiliary Tract and Pancreas: Elevated liver function tests, hepatitis, hyperbilirubinemia, jaundice.
Musculoskeletal: Myalgia. Skin and Subcutaneous Tissue Disorders: Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM), rashes including photosensitivity, alopecia, pruritus, urticaria (see CONTRAINDICATIONS and WARNINGS).
Special Senses: Visual abnormalities. Urogenital: Renal failure, renal pain (may be associated with renal failure), elevated blood urea nitrogen, elevated creatinine, hematuria (see WARNINGS). To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Monitoring parameters
- Kidney function and hydration. Neurotoxicity (confusion, hallucinations, dysarthria, seizures) is most common in end-stage kidney disease (ESKD) and older adults, including at adjusted doses; stop the drug and consider hemodialysis if it occurs. Kidney
- Kidney function (dose by creatinine clearance; renal failure reported)
- Neurologic status in older adults and in kidney impairment
Pharmacokinetics
Key PK parameters
| Bioavailability | 10% to 20% (falls as the dose rises) |
|---|---|
| Half-life | 2.5 to 3.3 hours |
| Half-life in kidney failure (ESKD) kidney | About 19.5 hours in anuria (IV label Table 2); about 5 hours during hemodialysis |
| Volume of distribution | About 1 L/kg (Vdss in children, IV label Table 3) |
| Protein binding | 9% to 33% |
| Metabolism (CYP, transporters) | Only known urinary metabolite: 9-[(carboxymethoxy)methyl]guanine |
| Renal excretion kidney | 62% to 91% unchanged in urine (IV label) |
| Dialyzability kidney | Yes: half-life about 5 hours during hemodialysis; a 6-hour session lowers plasma levels by about 60%. PD: no supplemental dose after interval adjustment (label). |
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2.
The only known urinary metabolite is 9-[(carboxymethoxy)methyl]guanine.
Special Populations: Adults With Impaired Renal Function: The half-life and total body clearance of acyclovir are dependent on renal function.
Mean half-life after oral doses of 300 mg/m 2 and 600 mg/m 2 in pediatric patients aged 7 months to 7 years was 2.6 hours (range 1.59 to 3.74 hours).
Drug Interactions: Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Pharmacokinetics: The pharmacokinetics of acyclovir after oral administration have been evaluated in healthy volunteers and in immunocompromised patients with herpes simplex or varicella-zoster virus infection. Acyclovir pharmacokinetic parameters are summarized in Table 1. Table 1. Acyclovir Pharmacokinetic Characteristics (Range) *Bioavailability decreases with increasing dose.
Parameter Range Plasma protein binding 9% to 33% Plasma elimination half-life 2.5 to 3.3 hr Average oral bioavailability 10% to 20%* In one multiple-dose, crossover study in healthy subjects (n = 23), it was shown that increases in plasma acyclovir concentrations were less than dose proportional with increasing dose, as shown in Table 2. The decrease in bioavailability is a function of the dose and not the dosage form.
Table 2. Acyclovir Peak and Trough Concentrations at Steady State Parameter 200 mg 400 mg 800 mg C SS max 0.83 mcg/mL 1.21 mcg/mL 1.61 mcg/mL C SS trough 0.46 mcg/mL 0.63 mcg/mL 0.83 mcg/mL There was no effect of food on the absorption of acyclovir (n = 6); therefore, acyclovir tablets may be administered with or without food.
The only known urinary metabolite is 9-[(carboxymethoxy)methyl]guanine. Special Populations: Adults With Impaired Renal Function: The half-life and total body clearance of acyclovir are dependent on renal function. A dosage adjustment is recommended for patients with reduced renal function (see DOSAGE AND ADMINISTRATION).
Geriatrics: Acyclovir plasma concentrations are higher in geriatric patients compared with younger adults, in part due to age-related changes in renal function. Dosage reduction may be required in geriatric patients with underlying renal impairment (see PRECAUTIONS: Geriatric Use). Pediatrics: In general, the pharmacokinetics of acyclovir in pediatric patients is similar to that of adults.
Mean half-life after oral doses of 300 mg/m 2 and 600 mg/m 2 in pediatric patients aged 7 months to 7 years was 2.6 hours (range 1.59 to 3.74 hours). Drug Interactions: Coadministration of probenecid with intravenous acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve.
Urinary excretion and renal clearance were correspondingly reduced. Clinical Trials: Initial Genital Herpes: Double-blind, placebo-controlled studies have demonstrated that orally administered acyclovir significantly reduced the duration of acute infection and duration of lesion healing. The duration of pain and new lesion formation was decreased in some patient groups.
Recurrent Genital Herpes: Double-blind, placebo-controlled studies in patients with frequent recurrences (6 or more episodes per year) have shown that orally administered acyclovir given daily for 4 months to 10 years prevented or reduced the frequency and/or severity of recurrences in greater than 95% of patients. In a study of patients who received acyclovir 400 mg twice daily for 3 years, 45%, 52%, and 63% of patients remained free of recurrences in the first, second, and third years, respectively.
Serial analyses of the 3-month recurrence rates for the patients showed that 71% to 87% were recurrence free in each quarter. Herpes Zoster Infections: In a double-blind, placebo-controlled study of immunocompetent patients with localized cutaneous zoster infection, acyclovir (800 mg 5 times daily for 10 days) shortened the times to lesion scabbing, healing, and complete cessation of pain, and reduced the duration of viral shedding and the duration of new lesion formation.
In a similar double-blind, placebo-controlled study, acyclovir (800 mg 5 times daily for 7 days) shortened the times to complete lesion scabbing, healing, and cessation of pain; reduced the duration of new lesion formation; and reduced the prevalence of localized zoster-associated neurologic symptoms (paresthesia, dysesthesia, or hyperesthesia). Treatment was begun within 72 hours of rash onset and was most effective if started within the first 48 hours.
Adults greater than 50 years of age showed greater benefit. Chickenpox: Three randomized, double-blind, placebo-controlled trials were conducted in 993 pediatric patients aged 2 to 18 years with chickenpox. All patients were treated within 24 hours after the onset of rash. In 2 trials, acyclovir was administered at 20 mg/kg 4 times daily (up to 3,200 mg per day) for 5 days.
In the third trial, doses of 10, 15, or 20 mg/kg were administered 4 times daily for 5 to 7 days. Treatment with acyclovir shortened the time to 50% healing; reduced the maximum number of lesions; reduced the median number of vesicles; decreased the median number of residual lesions on day 28; and decreased the proportion of patients with fever, anorexia, and lethargy by day 2.
Treatment with acyclovir did not affect varicella-zoster virus-specific humoral or cellular immune responses at 1 month or 1 year following treatment.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ACYCLOVIR · Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. [US FDA-approved label, version 6, July 24, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0de2f5c7-9e75-4bdf-9c28-e026cc6694b4
- U.S. Food and Drug Administration. Acyclovir Sodium · ProPharma Distribution [US FDA-approved label, version 3, July 18, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23a7cf9e-f21b-06c2-e063-6394a90aa623
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. (2026). Acyclovir tablets, USP (acyclovir) [Prescribing information; US FDA-approved label, ANDA074891, set ID 0de2f5c7-9e75-4bdf-9c28-e026cc6694b4, version effective July 24, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0de2f5c7-9e75-4bdf-9c28-e026cc6694b4
- ProPharma Distribution. (2025). Acyclovir sodium injection (acyclovir sodium) [Prescribing information; US FDA-approved label, ANDA203701, set ID 23a7cf9e-f21b-06c2-e063-6394a90aa623, version effective July 18, 2025]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23a7cf9e-f21b-06c2-e063-6394a90aa623
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
- Brandariz-Nuñez, D., Correas-Sanahuja, M., Maya-Gallego, S., & Martín Herranz, I. (2021). Neurotoxicity associated with acyclovir and valacyclovir: A systematic review of cases. Journal of Clinical Pharmacy and Therapeutics, 46(4), 918–926. https://doi.org/10.1111/jcpt.13464
- Hoskote, S. S., Annapureddy, N., Ramesh, A. K., Rose, K., & Jones, J. P. (2016). Valacyclovir and acyclovir neurotoxicity with status epilepticus. American Journal of Therapeutics, 23(1), e304–e306. https://doi.org/10.1097/MJT.0000000000000003
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .
US label: intravenous
Indications and usage (US label) US FDA label
INDICATIONS AND USAGE Herpes Simplex Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. Initial Episodes of Herpes Genitalis Acyclovir Sodium Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immuno-competent patients.
Herpes Simplex Encephalitis Acyclovir Sodium Injection is indicated for the treatment of herpes simplex encephalitis. Neonatal Herpes Simplex Virus Infection Acyclovir Sodium Injection is indicated for the treatment of neonatal herpes infections. Varicella-Zoster Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients.
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION CAUTION - RAPID OR BOLUS INTRAVENOUS INJECTION MUST BE AVOIDED (see WARNINGS and PRECAUTIONS). INTRAMUSCULAR OR SUBCUTANEOUS INJECTION MUST BE AVOIDED (see WARNINGS). Therapy should be initiated as early as possible following onset of signs and symptoms of herpes infections. A maximum dose equivalent to 20 mg/kg every 8 hours should not be exceeded for any patient.
Dosage HERPES SIMPLEX INFECTIONS MUCOSAL AND CUTANEOUS HERPES SIMPLEX (HSV-1 AND HSV-2) INFECTIONS IN IMMUNOCOMPROMISED PATIENTS Adults and Adolescents (12 years of age and older) 5 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. Pediatrics (Under 12 years of age) 10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days.
SEVERE INITIAL CLINICAL EPISODES OF HERPES GENITALIS Adults and Adolescents (12 years of age and older) 5 mg/kg infused at a constant rate over 1 hour, every 8 hours for 5 days. HERPES SIMPLEX ENCEPHALITIS Adults and Adolescents (12 years of age and older) 10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days.
Pediatrics (3 months to 12 years of age) 20 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days. Neonatal Herpes Simplex Virus Infections (Birth to 3 months) 10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days. In neonatal herpes simplex infections, doses of 15 mg/kg or 20 mg/kg (infused at a constant rate over 1 hour every 8 hours) have been used; the safety and efficacy of these doses are not known.
VARICELLA-ZOSTER INFECTIONS ZOSTER IN IMMUNOCOMPROMISED PATIENTS Adults and Adolescents (12 years of age and older) 10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. Pediatrics (Under 12 years of age) 20 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. Obese Patients Obese patients should be dosed at the recommended adult dose using Ideal Body Weight.
PATIENTS WITH ACUTE OR CHRONIC RENAL IMPAIRMENT Refer to DOSAGE AND ADMINISTRATION section for recommended doses, and adjust the dosing interval as indicated in Table 5. Table 5: Dosage Adjustments for Patients with Renal Impairment Creatinine Clearance (mL/min/1.73 m²) Percent of Recommended Dose Dosing Interval (hours) >50 100% 8 25 to 50 100% 12 10 to 25 100% 24 0 to 10 50% 24 Hemodialysis For patients who require dialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours.
This results in a 60% decrease in plasma concentrations following a six-hour dialysis period. Therefore, the patient’s dosing schedule should be adjusted so that an additional dose is administered after each dialysis. Peritoneal Dialysis No supplemental dose appears to be necessary after adjustment of the dosing interval.
Administration The calculated dose should be further diluted in an appropriate intravenous solution at a volume selected for administration during each 1 hour infusion. Infusion concentrations of approximately 7 mg/mL or lower are recommended. In clinical studies, the average 70 kg adult received between 60 and 150 mL of fluid per dose.
Higher concentrations (e.g., 10 mg/mL) may produce phlebitis or inflammation at the injection site upon inadvertent extravasation. Standard, commercially available electrolyte and glucose solutions are suitable for intravenous administration; biologic or colloidal fluids (e.g., blood products, protein solutions, etc.) are not recommended.
Once diluted for administration, each dose should be used within 24 hours. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Kidney dosing: Renal impairment (US label) US FDA label
Patients with Renal Impairment Creatinine Clearance (mL/min/1.73 m²) Percent of Recommended Dose Dosing Interval (hours) >50 100% 8 25 to 50 100% 12 10 to 25 100% 24 0 to 10 50% 24 Hemodialysis For patients who require dialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours. This results in a 60% decrease in plasma concentrations following a six-hour dialysis period.
Therefore, the patient’s dosing schedule should be adjusted so that an additional dose is administered after each dialysis. Peritoneal Dialysis No supplemental dose appears to be necessary after adjustment of the dosing interval. Administration The calculated dose should be further diluted in an appropriate intravenous solution at a volume selected for administration during each 1 hour infusion.
Infusion concentrations of approximately 7 mg/mL or lower are recommended. In clinical studies, the average 70 kg adult received between 60 and 150 mL of fluid per dose. Higher concentrations (e.g., 10 mg/mL) may produce phlebitis or inflammation at the injection site upon inadvertent extravasation. Standard, commercially available electrolyte and glucose solutions are suitable for intravenous administration; biologic or colloidal fluids (e.g., blood products, protein solutions, etc.) are not recommended.
Once diluted for administration, each dose should be used within 24 hours. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Impaired Renal Function Acyclovir was administered at a dose of 2.5 mg/kg to 6 adult patients with severe renal failure. The peak and trough plasma levels during the 47 hours preceding hemodialysis were 8.5 mcg/mL and 0.7 mcg/mL, respectively. Consult DOSAGE AND ADMINISTRATION section for recommended adjustments in dosing based upon creatinine clearance.
Warnings and precautions (US label) US FDA label
WARNINGS Acyclovir Sodium Injection is intended for intravenous infusion only, and should not be administered topically, intramuscularly, orally, subcutaneously, or in the eye. Intravenous infusions must be given over a period of at least 1 hour to reduce the risk of renal tubular damage (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).
Renal failure, in some cases resulting in death, has been observed with acyclovir therapy (see ADVERSE REACTIONS, Observed During Clinical Practice and OVERDOSAGE). Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy.
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The adverse reactions listed below have been observed in controlled and uncontrolled clinical trials in approximately 700 patients who received acyclovir at approximately 5 mg/kg (250 mg/m 2) 3 times daily, and approximately 300 patients who received approximately 10 mg/kg (500 mg/m 2) 3 times daily. The most frequent adverse reactions reported during administration of acyclovir were inflammation or phlebitis at the injection site in approximately 9% of the patients, and transient elevations of serum creatinine or BUN in 5% to 10% (the higher incidence occurred usually following rapid [less than 10 minutes] intravenous infusion).
Nausea and/or vomiting occurred in approximately 7% of the patients (the majority occurring in nonhospitalized patients who received 10 mg/kg). Itching, rash, or hives occurred in approximately 2% of patients. Elevation of transaminases occurred in 1% to 2% of patients. The following hematologic abnormalities occurred at a frequency of less than 1%: anemia, neutropenia, thrombocytopenia, thrombocytosis, leukocytosis, and neutrophilia.
In addition, anorexia and hematuria were observed. Observed During Clinical Practice In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of Acyclovir Sodium Injection in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made.
These events have been chosen for inclusion due to either their seriousness, frequency of reporting, potential causal connection to acyclovir, or a combination of these factors. General: Anaphylaxis, angioedema, fatigue, fever, headache, pain, peripheral edema. Digestive: Abdominal pain, diarrhea, gastrointestinal distress, nausea.
Cardiovascular: Hypotension. Hematologic and Lymphatic: Disseminated intravascular coagulation, hemolysis, leukocytoclastic vasculitis, leukopenia, lymphadenopathy. Hepatobiliary Tract and Pancreas: Elevated liver function tests, hepatitis, hyperbilirubinemia, jaundice. Musculoskeletal: Myalgia. Nervous: Aggressive behavior, agitation, ataxia, coma, confusion, delirium, dizziness, dysarthria, encephalopathy, hallucinations, obtundation, paresthesia, psychosis, seizure, somnolence, tremor.
These symptoms may be marked, particularly in older adults (see PRECAUTIONS). Skin: Alopecia, erythema multiforme, photosensitive rash, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria. Severe local inflammatory reactions, including tissue necrosis, have occurred following infusion of acyclovir into extravascular tissues.
Special Senses: Visual abnormalities. Urogenital: Renal failure, elevated blood urea nitrogen, elevated creatinine (see WARNINGS).
Pediatric use (US label) US FDA label
Pediatric Use See DOSAGE AND ADMINISTRATION.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Pharmacokinetics The pharmacokinetics of acyclovir after intravenous administration have been evaluated in adult patients with normal renal function during Phase 1/2 studies after single doses ranging from 0.5 to 15 mg/kg and after multiple doses ranging from 2.5 to 15 mg/kg every 8 hours. Proportionality between dose and plasma levels is seen after single doses or at steady-state after multiple dosing.
Average steady-state peak and trough concentrations from 1-hour infusions administered every 8 hours are given in Table 1. Table 1: Acyclovir Peak and Trough Concentrations at Steady-State Dosage Regimen C SS max C SS trough 5 mg/kg q 8 h (n = 8) 9.8 mcg/mL range: 5.5 to 13.8 0.7 mcg/mL range: 0.2 to 1 10 mg/kg q 8 h (n = 7) 22.9 mcg/mL range: 14.1 to 44.1 1.9 mcg/mL range: 0.5 to 2.9 Concentrations achieved in the cerebrospinal fluid are approximately 50% of plasma values.
Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated. Renal excretion of unchanged drug is the major route of acyclovir elimination accounting for 62% to 91% of the dose. The only major urinary metabolite detected is 9-carboxymethoxymethylguanine accounting for up to 14.1% of the dose in patients with normal renal function.
The half-life and total body clearance of acyclovir are dependent on renal function as shown in Table 2. Table 2: Acyclovir Half-life and Total Body Clearance Creatinine Clearance (mL/min/1.73 m²) Half-Life (hr) Total Body Clearance (mL/min/1.73 m²) (mL/min/kg) >80 2.5 327 5.1 50 to 80 3 248 3.9 15 to 50 3.5 190 3.4 0 (Anuric) 19.5 29 0.5 Special Populations Adults With Impaired Renal Function Acyclovir was administered at a dose of 2.5 mg/kg to 6 adult patients with severe renal failure.
The peak and trough plasma levels during the 47 hours preceding hemodialysis were 8.5 mcg/mL and 0.7 mcg/mL, respectively. Consult DOSAGE AND ADMINISTRATION section for recommended adjustments in dosing based upon creatinine clearance. Pediatrics Acyclovir pharmacokinetics were determined in 16 pediatric patients with normal renal function ranging in age from 3 months to 16 years at doses of approximately 10 mg/kg and 20 mg/kg every 8 hours (Table 3).
Concentrations achieved at these regimens are similar to those in adults receiving 5 mg/kg and 10 mg/kg every 8 hours, respectively (Table 1). Acyclovir pharmacokinetics were determined in 12 patients ranging in age from birth to 3 months at doses of 5 mg/kg, 10 mg/kg, and 15 mg/kg every 8 hours (Table 3). Table 3: Acyclovir Pharmacokinetics in Pediatric Patients (Mean ±SD) Parameter Birth to 3 Months of Age (n = 12) 3 Months to 12 Years of Age (n = 16) CL (mL/min/kg) 4.46 ± 1.61 8.44 ± 2.92 VDSS (L/kg) 1.08 ± 0.35 1.01 ± 0.28 Elimination half-life (hours) 3.8 ± 1.19 2.36 ± 0.97 Geriatrics Acyclovir plasma concentrations are higher in geriatric patients compared to younger adults, in part due to age-related changes in renal function.
Dosage reduction may be required in geriatric patients with underlying renal impairment (see PRECAUTIONS, Geriatric Use). Drug Interactions Coadministration of probenecid with acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. Urinary excretion and renal clearance were correspondingly reduced.
Clinical Trials Herpes Simplex Infections in Immunocompromised Patients A multicenter trial of acyclovir at a dose of 250 mg/m 2 every 8 hours (750 mg/m 2 /day) for 7 days was conducted in 98 immunocompromised patients (73 adults and 25 children) with orofacial, esophageal, genital and other localized infections (52 treated with acyclovir and 46 with placebo). Acyclovir decreased virus excretion, reduced pain, and promoted healing of lesions.
Initial Episodes of Herpes Genitalis In placebo-controlled trials, 58 patients with initial genital herpes were treated with intravenous acyclovir 5 mg/kg or placebo (27 patients treated with acyclovir and 31 treated with placebo) every 8 hours for 5 days. Acyclovir decreased the duration of viral excretion, new lesion formation, and duration of vesicles, and promoted healing of lesions.
Herpes Simplex Encephalitis Sixty-two patients ages 6 months to 79 years with brain biopsy-proven herpes simplex encephalitis were randomized to receive either acyclovir (10 mg/kg every 8 hours) or vidarabine (15 mg/kg/day) for 10 days (28 were treated with acyclovir and 34 with vidarabine). Overall mortality at 12 months for patients treated with acyclovir was 25% compared to 59% for patients treated with vidarabine.
The proportion of patients treated with acyclovir functioning normally or with only mild sequelae (e.g., decreased attention span) was 32% compared to 12% of patients treated with vidarabine. Patients less than 30 years of age and those who had the least severe neurologic involvement at time of entry into study had the best outcome with treatment with acyclovir.
An additional controlled study performed in Europe demonstrated similar findings. Neonatal Herpes Simplex Virus Infection Two hundred and two infants with neonatal herpes simplex infections were randomized to receive either acyclovir 10 mg/kg every 8 hours (n = 107) or vidarabine 30 mg/kg/day (n = 95) for 10 days. Outcomes are presented in Table 4.
Table 4: Mortality at 1 Year * SEM refers to localized infection with disease limited to skin, eye, and/or mouth. † CNS refers to infection of the central nervous system with compatible neurologic and CSF findings. ‡ DISS refers to visceral organ involvement such as hepatitis or pneumonitis with or without CNS involvement. HSV Disease Classification Treatment Group Acyclovir (n = 107) Vidarabine (n = 95) SEM* (n = 85) 0/54 0/31 CNS † (n = 71) 5/35 5/36 DISS ‡ (n = 46) 11/18 14/28 Rates of neurologic sequelae at 1 year were comparable between the treatment groups.
Varicella-Zoster Infections in Immunocompromised Patients A multicenter trial of acyclovir at a dose of 500 mg/m 2 every 8 hours for 7 days was conducted in immunocompromised patients with zoster infections (shingles). Ninety-four (94) patients were evaluated (52 patients were treated with acyclovir and 42 with placebo).
Acyclovir was superior to placebo as measured by reductions in cutaneous dissemination and visceral dissemination.
